Entyvio Improves Remission Rates in Ulcerative Colitis, Crohn's Disease

Real-world clinical data highlighting the safety and efficacy of vedolizumab (Entyvio) for the treatment of adults with moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD) was presented at the 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas.

Entyvio is a humanized monoclonal antibody that binds to the alpha4beta7 integrin, blocking the interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibiting the migration of memory T-lymphocytes into the gastrointestinal parenchymal tissue.

The presentation examined reports that included more than 7700 patients with moderate-to-severe active UC or CD who were treated with Entyvio. Investigators analyzed treatment benefit and safety profile with Entyvio from their review patients, according to a press release.

“Findings from our comprehensive data review support previous clinical trial findings regarding remission rates and reductions in disease activity scores in many patients with moderate-to-severe UC and CD receiving treatment with vedolizumab,” said study co-author and lead presenter Dirk Demuth. “This systemic review offers a unique perspective into the real-world impact of vedolizumab treatment for a large cross-section of patients, adding to the growing body of information about both the safety and effectiveness profile of vedolizumab as a treatment option for patients living with moderate-to-severe UC or CD.”

Other presentations at ACG included additional real-world vedolizumab data, as well as 2 abstracts focused on real-world treatment persistence.

“We are pleased to contribute to the ongoing study of vedolizumab and have this opportunity to share findings from a dynamic selection of real-world studies, offering insights into the use of vedolizumab,” said Karen Lasch, medical director, Gastroenterology, Takeda Pharmaceuticals, and co-author of 2 vedolizumab abstracts “Since Takeda launched vedolizumab more than 2 years ago in the US, we continue to build upon the outcomes of our clinical trials with real world evidence supporting the importance of this treatment option for the UC and CD communities.”

Entyvio is the first and only biologic approved simultaneously for the treatment of adults with severely active UC or CD who have had an inadequate response, lost response, or were intolerant to conventional therapy or a tumor necrosis factor-alpha antagonist